HLA-C and neoplasm: Adoptive cell therapies (ACT) also encompass ex vivo expansion and infusion of tumor-infiltrating lymphocytes (TILs) [5] and genetic redirection of non-therapeutic endogenous lymphocytes with a TCR which recognizes a tumor-specific antigen presented through the MHC [6].